๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› China
Clinical trial register · China

Studies with a Chinese investigative site

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the register
Recruitment status
Phase
Lead sponsor
Sun Yat-sen University490 Fudan University472 Second Affiliated Hospital, Zhejiang University, School of Medicine404 Peking Union Medical College Hospital282 Ruijin Hospital281
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to
19052 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Active, closed
Long-term Safety and Tolerability of HRS-5965 in Patients With Paroxysmal Nocturnal Hemoglobinuria
NCT06238544Paroxysmal Nocturnal Hemoglobinuria
Chengdu Suncadia Medicine Co., Ltd.
Phase 2
132
Beijing, Tianjin
2024-02-06
Active, closed
TDI01 Suspension in the Treatment of Chronic Graft-versus-host Disease (cGVHD))
NCT06169722GVHD, Chronic
Beijing Tide Pharmaceutical Co., Ltd
Phase 1/2
60
Beijing
2024-02-06
Recruiting
HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced Solid Tumors
NCT06112704Advanced Solid Tumor
Hansoh BioMedical R&D Company
Phase 2
220
Hefei, Fujian, Fuzhou, Guangzhou, Harbin, Anyang, Luoyang, Nanyang
2024-02-06
Recruiting
The "Quit-for-Kids" Project: to Increase Abstinence and Protect Children From Tobacco Smoke Exposure
NCT06127589Smoking Cessation, Second Hand Tobacco Smoke
The University of Hong Kong
Not applicable
1,200
Hong Kong
2024-02-05
Recruiting
Ultrasound-Guided Hydrodilatation With Triamcinolone Acetonide for Adhesive Capsulitis
NCT06553716Postoperation Pain
General Hospital of Ningxia Medical University
Not applicable
70
Yinchuan
2024-02-05
Recruiting
SHR2554 Clinical Study of Chidamide in the Treatment of T-cell Lymphoma
NCT06122389Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
130
Beijing
2024-02-05
Active, closed
Real-world First-line Serplulimab-based Immunochemotherapy for Extensive-stage Small Cell Lung Cancer
NCT06748495Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Hunan Cancer Hospital
Observational
600
Changsha
2024-02-05
Recruiting
A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer
NCT06194734Esophageal Squamous Cell Carcinoma
Beijing Konruns Pharmaceutical Co., Ltd.
Phase 3
490
Beijing
2024-02-05
Recruiting
Refractory ANCA Associated Vasculitis and Lupus Nephritis Treated With BCMA-targeting CAR-T Cells
NCT06277427Lupus Nephritis, ANCA Associated Vasculitis
Lingli Dong
Not applicable
24
Wuhan
2024-02-05
Active, closed
A Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
NCT06198751Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
104
Chongqing, Fuzhou, Guiyang, Harbin, Changsha, Shenyang, Shanghai
2024-02-05
Recruiting
Early-stage Detection of Liver Cancer by Proteins in Peripheral Blood
NCT06544083Hepatocellular Carcinoma
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
600
Hangzhou
2024-02-05
Recruiting
RDC-Blinatumomab Versus hyperCVAD for Ph-negative B-ALL.
NCT06250959ALL, Adult, Philadelphia-Negative ALL
Chen Suning
Phase 2
124
Suzhou
2024-02-05
Recruiting
Node-sparing Radiotherapy Combined With Total Neoadjuvant CAPOX and Sintilimab for MSS Middle and Low Rectal Cancer
NCT06204094Locally Advanced Rectal Cancer
Jinhua Central Hospital
Phase 2
37
Jinhua
2024-02-05
Active, closed
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
NCT06191744Follicular Lymphoma (FL)
Genmab
Phase 3
1,095
Beijing, Xiamen, Guangzhou, Shenzhen, Nanning, Zhengzhou, Wuhan, Changsha
2024-02-05
Not yet open
HR070803 in Combination With Oxaliplatin, 5-fluorouracil/LV Versus GX as Adjuvant Therapy for Pancreatic Cancer
NCT06217042Pancreatic Cancer
Fudan University
Phase 3
524
Shanghai
2024-02-05
Recruiting
PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal Cancer
NCT06086457Esophageal Neoplasms
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3
436
Beijing
2024-02-04
Recruiting
Pegylated Interferon ฮฑ in Previously Interferon-treated CHB๏ผˆLeading Study๏ผ‰
NCT06323681Chronic Hepatitis b
Qing XIe
Not applicable
2,016
Shanghai
2024-02-04
Recruiting
Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation
NCT06243354Safety, Tolerability, Efficacy
Sichuan Huiyu Pharmaceutical Co., Ltd
Phase 1/2
257
Fuzhou, Changsha, Shenyang, Jinan, Shanghai, Chengdu
2024-02-04
Active, closed
CNCT19 for Patients With Autoimmune Hemolytic Anemia After Failure โ‰ฅ3 Lines of Therapy.
NCT06231368Autoimmune Hemolytic Anemia, Autologous CD19 CAR-T, Failure of Three or More Lines of Therapy
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
6
Tianjin
2024-02-04
By invitation
An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of ND-003 in Patients With Advanced Solid Cancers
NCT06169579Advanced Solid Tumor
Shenzhen NewDEL Biotech, Co., Ltd
Phase 1
96
Xiamen, Lanzhou, Guangzhou, Shenzhen, Zhanjiang, Nanning, Guiyang, Wuโ€™an
2024-02-04
Recruiting
A Prospective, Multicenter, and Exploratory Study of CMGV in the Treatment of Recurrent Adult AML and MDS-EB-2/Elder AML
NCT06329999Recurrent Adult Acute Myeloid Leukemia, Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia
Ruijin Hospital
Not applicable
78
Shanghai
2024-02-03
Not yet open
Efficacy and Safety of Sintilimab Combined With Nab-paclitaxel and Tegio (aTS) as First-line Treatment of Unresectable Locally Advanced, Recurrent or Metastatic Adenocarcinoma of Gastric and Gastroesophageal Junction๏ผŒa Phase II Clinical Study
NCT06241469Gastric Cancer, GastroEsophageal Cancer, Adenocarcinoma
Wu Jun
Phase 2
40
Changzhou
2024-02-03
Recruiting
Fluorescence Guided Laparoscopic-Endoscopic Cooperative Sentinel Lymph Node Navigation Surgery Strategy for Early Gastric Cancer๏ผˆIDEAL Stage 2b๏ผ‰
NCT06788548Early Gastric Cancer
Beijing Friendship Hospital
Not applicable
312
Beijing
2024-02-03
Recruiting
Study SC-101 in Subjects With Advanced Malignancies
NCT06220838Advanced Solid Tumor
Tianjin ConjuStar Biologics Co., Ltd.
Phase 1
100
Beijing, Changsha, Nanjing, Shanghai, Tianjin
2024-02-02
Recruiting
Safety and Efficacy Study for DC Vaccine in Recurrent or Progressive High-grade Gliomas
NCT06253234WHO Grade III Gliomas, WHO Grade IV Gliomas
Beijing Tiantan Hospital
Phase 1
12
Beijing
2024-02-02
Recruiting
SABR Combined With Targeted Therapy and Anti-PD-1 for Recurrent or Metastatic Renal Cancer
NCT06583070Radiation Therapy, Metastatic Renal Cancer, Recurrent Renal Cell Cancer
Peking University First Hospital
Observational
300
Beijing
2024-02-02
Recruiting
Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases
NCT06265350Hepatocellular Carcinoma, Liver Cancer Stage IV, Pulmonary Metastases, Cadonilimab
Sun Yat-sen University
Not applicable
80
Guanzhou
2024-02-02
Recruiting
Sintilimab With Chemotherapy Plus PEG-rhG-GSF for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma
NCT06563869Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital with Nanjing Medical University
Phase 3
40
Nanjing
2024-02-02
Recruiting
Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expression
NCT06749860Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
58
Shanghai
2024-02-02
Recruiting
A Comprehensive Registry Study of the Whole Life Cycle of Patients With CHD
NCT06611787Congenital Heart Disease
Beijing Anzhen Hospital
Observational
100,000
Beijing
2024-02-02
Recruiting
Toripalimab Combined With Definitive CCRT for LACC Patients
NCT06256224Cervical Cancer, Chemoradiotherapy, Immunotherapy
Ruijin Hospital
Not applicable
150
Shanghai
2024-02-02
Recruiting
Efficacy of Immunosuppressive Therapy for IgA Nephropathy With Stage 3 or 4 CKD
NCT05510323Glomerulonephritis, IGA
Air Force Military Medical University, China
Phase 3
208
Xi'an
2024-02-01
Recruiting
Hypofractionated Post-prostatectomy Radiotherapy (HYPORT)for Localized Prostate Cancer
NCT06325995Localized Prostate Cancer
Changhai Hospital
Not applicable
428
Shanghai
2024-02-01
Recruiting
CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+
NCT06355739B Lymphocytic Leukemia, B Lymphoblastic Lymphoma
Zhu Xiaofan
Not applicable
60
Tianjin
2024-02-01
Recruiting
Peking University Birth Cohort in Weifang (PKUBC-WF)
NCT06234332Health Problems in Pregnancy, Pregnancy Outcomes, Gestational Diabetes, Gestational Hypertension
Peking University
Observational
2,800
Beijing
2024-02-01
Active, closed
Superior Vena Cava Isolation Plus Pulmonary Vein Isolation for Paroxysmal Atrial Fibrillation
NCT06183619Atrial Fibrillation
Chinese Academy of Medical Sciences, Fuwai Hospital
Observational
400
Beijing
2024-02-01
Recruiting
Efficacy and Safety of CAR-T Cells Therapy for Chronic or Refractory Primary Immune Thrombocytopenia (ITP)
NCT06352281ITP - Immune Thrombocytopenia
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Phase 1/2
10
Kunming
2024-02-01
Recruiting
Application of Transbronchial Cryobiopsy in the Diagnosis of Progressive Pulmonary Fibrosis
NCT06251687Pulmonary Fibrosis, Transbronchial Cryobiopsy
China-Japan Friendship Hospital
Not applicable
100
Beijing
2024-02-01
Recruiting
Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer
NCT06447623Advanced Breast Cancer, HR+/HER2- Breast Cancer
Fudan University
Phase 3
184
Shanghai
2024-02-01
Recruiting
Teniposide, Cisplatin and Serplulimab for Treatment of ES-SCLC, a Randomized Controlled Study
NCT07583511Small-cell Lung Cancer
Sun Yat-sen University
Phase 2
90
Guangzhou
2024-02-01
Recruiting
Analysis of the Incidence and Risk Factors of Chronic Pain After Cesarean Section
NCT06704490Postoperative Pain, Cesarean Section Surgery
Huazhong University of Science and Technology
Observational
600
Wuhan
2024-02-01
Recruiting
Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients
NCT06280495Colorectal Cancer, Liver Metastases
Sun Yat-sen University
Phase 2/3
156
Guangzhou
2024-02-01
Recruiting
A Study of Factors Influencing Recurrence After Thermal Ablation of Papillary Thyroid Carcinoma
NCT05962892Papillary Thyroid Carcinoma, Thermal Ablation
Beijing Friendship Hospital
Observational
600
Beijing
2024-02-01
Recruiting
Oxygen Concentration Target in Stroke Endovascular Treatment
NCT06224426Ischemic Stroke
Beijing Tiantan Hospital
Not applicable
200
Beijing
2024-02-01
Recruiting
Cadonilimab (AK104) Combined With Chemotherapy and Bevacizumab as First-line Treatment for RAS Mutated or Right Sided-metastatic MSS Colorectal Cancer
NCT06566755Colorectal Cancer
Caigang Liu
Phase 3
30
Shenyang
2024-02-01
Recruiting
A Multi-center, Randomized, Double-blind, Phase II/III Clinical Trial of AK104 or Placebo in Combination With Chemotherapy as Second-line or More Lines for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
NCT06241599Recurrent or Metastatic Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2/3
300
Guangzhou
2024-02-01
By invitation
Phase II Clinical Study of Contezolid for the Treatment of Tuberculous Meningitis
NCT06811025Tuberculosis, Meningitis
Beijing Chest Hospital
Phase 1/2
24
Beijing
2024-02-01
Not yet open
A Randomized Controlled Trial for Surgical Treatment of Recurrent Adult Tethered Cord Syndrome
NCT06197399Recurrent Adult Tethered Cord Syndrome
Xuanwu Hospital, Beijing
Not applicable
222
Beijing
2024-02-01
Recruiting
Brain Monitoring During PEEP-Based Respiratory Therapy in Critically Ill Patients
NCT07716787Acute Brain Injury, Mechanical Ventilation, Neurocritical Care
Shengli Oilfield Hospital
Not applicable
50
Dongying
2024-02-01
Recruiting
Safety and Effectiveness of Sulfasalazine in the Treatment of Liver Fibrosis/Cirrhosis.
NCT06293378Cirrhosis, Liver, Fibrosis, Liver
The Second Affiliated Hospital of Chongqing Medical University
Not applicable
330
Chongqing
2024-02-01
Recruiting
MRD-guided Prognosis Prediction and Adjuvant Treatment Based on CTC and ctDNA in NSCLC
NCT06198868Non-small Cell Lung Cancer
Jiangsu Cancer Institute & Hospital
Observational
60
Nanjing
2024-02-01
Recruiting
PD1 Inhibitors Combined With Clostridium Butyricum for Urothelial Carcinoma
NCT06696742Bladder (Urothelial, Transitional Cell) Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2
60
Nanjing
2024-02-01
Recruiting
Immune Dynamics in the Natural History of Chronic HBV Infection
NCT07137247HBV (Hepatitis B Virus), HBV Infection, Chronic Hep B
Nanfang Hospital, Southern Medical University
Observational
5,000
Guangzhou
2024-02-01
Recruiting
Extra Luteinizing Hormone Improve Embryo Quality in IVF Patients With Low LH During Long GnRH-Agonist Treatment
NCT07128394Infertility, Female, Luteinizing Hormone (LH)
Nanjing University
Not applicable
590
Nanjing
2024-02-01
Recruiting
Precision Diagnosis and Prospective Cohort Study for Myasthenia Gravis: Multicenter Analysis in China
NCT04535843Myasthenia Gravis
Huashan Hospital
Observational
500
Shanghai
2024-02-01
Recruiting
Non-Invasive Model for Fibrosis Regression in HBV Patients
NCT06874127Chronic Hepatitis B Virus (HBV) Infection, Liver Fibrosis
Beijing Friendship Hospital
Observational
1,100
Beijing
2024-02-01
Recruiting
Plasma SAA1 Levels in Predicting Response to Radiotherapy-induced Oral Mucositis
NCT06307314Nasopharyngeal Carcinoma, Head and Neck Cancer, Radiotherapy-induced Oral Mucositis, Biomarker
Nanfang Hospital, Southern Medical University
Observational
300
Guangzhou, Fuzhou, Huizhou, Jieyang, Meizhou
2024-02-01
Recruiting
VAC Regimen for AML Patients Who Failed to Response to VA Regimen
NCT06220162Acute Myeloid Leukemia
The First Affiliated Hospital of Soochow University
Phase 2
32
Suzhou
2024-02-01
Recruiting
Personalized Anticoagulant Therapy for Pulmonary Thromboembolism
NCT06341231Pulmonary Thromboembolisms, Anticoagulants; Increased
Xiangya Hospital of Central South University
Observational
4,700
Changsha
2024-02-01
Recruiting
Intravascular Radiofrequency Ablation of Sympathetic Nerves for the Treatment of Hepatocellular Carcinoma
NCT06694636Hepatocellular Carcinoma
Zhongda Hospital
Not applicable
5
Nanjing
2024-02-01
By invitation
Treatment of Relapsed or Refractory t(8; 21) AML With Targeted AML1-ETO Neoantigen Cytotoxic T Cells (CTL)
NCT06499025AML, t(8;21), Neoantigen
BGI, China
Phase EARLY_PHASE1
16
Shenzhen
2024-02-01
Recruiting
Molecular Characteristics of Hepatitis B Virus Integration, Mutation, and Drug Resistance
NCT06779864Chronic Hepatitis B
Beijing Friendship Hospital
Observational
2,000
Beijing
2024-02-01
Recruiting
ctDNA in HER2+ EBC Neoadjuvant Treatment
NCT07335081Breast Cancer
Shanghai Jiao Tong University School of Medicine
Phase 2
60
Shanghai
2024-02-01
Recruiting
Clinical Trial of TQB2922 for Injection in Patients With Advanced Cancers
NCT06188624Advanced Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
150
Chongqing, Guangzhou, Harbin, Zhengzhou, Changsha, Nanjing, Dalian, Shenyang
2024-02-01
Recruiting
Atropine (0.02%, 0.04%) Combined With Defocus DIMS for Moderate and High Myopia Control
NCT06523504Myopia
Ruihua Wei
Phase 1/2
410
Tianjin
2024-02-01
Not yet open
Anti-infection Therapy Based on mNGS Etiological Diagnosis and Infection After Liver Transplantation
NCT06212115Infection
Shenzhen Third People's Hospital
Observational
300
Shenzhen
2024-02-01
Recruiting
Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies
NCT05966467Neuromyelitis Optica Spectrum Disorder, NMOSD, AQP4+ NMOSD
Alexion Pharmaceuticals, Inc.
Observational
122
Beijing, Guangzhou, Henan, Shanghai, Sichuan, Wuhan
2024-02-01
Recruiting
Protein Molecular Characteristics and Prognosis of Cervical Neuroendocrine Tumors
NCT06276309Neuroendocrine Neoplasm, China, Women, Cervical Cancer
Fujian Maternity and Child Health Hospital
Observational
300
Fuzhou, Ningde, Putian, Quanzhou, Zhangzhou, Wuhan, Changsha, Nanchang
2024-02-01
Active, closed
Neoadjuvant Chemoradiation With Nal-IRI and Capecitabine Guided by UGT1A1 Status in Patients With Rectal Cancer
NCT06210971Rectal Cancer
Hebei Medical University Fourth Hospital
Phase 2
60
Shijiazhuang
2024-02-01
Recruiting
Myasthenia Gravis Registry in China
NCT06241521Myasthenia Gravis
Huashan Hospital
Observational
1,500
Beijing, Chongqing, Guangzhou, Zhengzhou, Changsha, Suzhou, Xuzhou, Nanchang
2024-02-01
Recruiting
The Efficacy of High-frequency Short-time Spinal Cord Stimulation in the Treatment of Herpes Zoster-associated Neuralgia
NCT06942806Herpes Zoster Pain
Li Zhao
Observational
74
Zunyi
2024-02-01
Recruiting
Study to Evaluate the Efficacy, Safety and Tolerability of Photodynamic Therapy(PDT) With Chlorin-e6 in Treating Moderate to Severe Acne
NCT06311890Acne, Photodynamic Therapy
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Phase 2
46
Beijing
2024-02-01
Recruiting
A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALL
NCT06220487Acute Lymphoblastic Leukemia, Philadelphia Chromosome, Philadelphia-Positive ALL, Adult ALL
Nanfang Hospital, Southern Medical University
Phase 2
67
Guangzhou
2024-02-01
Not yet open
Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations
NCT06054191NSCLC, BRAF V600 Mutation, MET Exon 14 Mutation
Sun Yat-sen University
Phase 2
40
Guangzhou
2024-02-01
Recruiting
Comparison of Cytokines Profile in Aqueous Humor and Tear Before and After UCP Treatment
NCT06243497Glaucoma, Ultrasound Cyclo Plasty, Aqueous Humor, Tear
Zhongshan Ophthalmic Center, Sun Yat-sen University
Observational
200
Guangzhou
2024-02-01
Recruiting
Tenecteplase for Acute Ischemic Stroke Within 4.5 to 6 Hours of Onset (EXIT-BT2)
NCT06010628Stroke, Ischemic
General Hospital of Shenyang Military Region
Phase 4
1,440
Shenyang
2024-02-01
Recruiting
High-Strength Suture vs. Traditional Tension Band for Patellar Fractures
NCT07248982Patella Fracture
Fuzhou University Affiliated Provincial Hospital
Observational
50
Fuzhou
2024-02-01
Recruiting
A Clinical Study of Darcilil Combined With AI Combined With Pyrrotinib in the Treatment of TPBC
NCT06235931Breast Neoplasms
Second Affiliated Hospital of Soochow University
Not applicable
34
Suzhou
2024-02-01
Active, closed
12-Month Real-World Safety & Efficacy of Lecanemab in Early Alzheimer's Disease
NCT07034222Alzheimer's Disease(AD)
Ruijin Hospital
Phase 4
80
Shanghai
2024-02-01
Recruiting
T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor
NCT06478251Tumor, Solid
TingBo Liang
Phase 1
9
Hangzhou
2024-02-01
Recruiting
Establishment and Evaluation of Prenatal Prevention and Treatment Strategy for NARDS
NCT06188195Acute Respiratory Distress Syndrome, Respiratory Distress Syndrome, Acute
The Second Affiliated Hospital of Chongqing Medical University
Not applicable
500
Chongqing
2024-02-01
Recruiting
Postoperative Anemia After Bariatric Surgery
NCT06198790Anemia, Bariatric Surgery Candidate
China-Japan Friendship Hospital
Observational
400
Beijing
2024-02-01
Recruiting
Single-drug Chemotherapy Plus Immunotherapy in Metastatic Non-small Cell Lung Cancer Elderly Patients
NCT06032052Elderly Patients, Metastatic Lung Cancer
Hubei Cancer Hospital
Phase 2
49
Wuhan
2024-02-01
Not yet open
Comparing Astragalus Plus Gemcitabine to Gemcitabine Alone as Neoadjuvant Treatment for Pancreatic Cancer Patients
NCT06234072Pancreatic Cancer
Shenzhen University General Hospital
Phase 2
120
Shenzhen
2024-02
Recruiting
The Therapeutic Effect of Thalidomide in Syringomyelia
NCT06268093Syringomyelia, Thalidomide
Xuanwu Hospital, Beijing
Phase 2
30
Beijing
2024-02
Active, closed
A Clinical Study Evaluating the Safety, Tolerability, and Initial Efficacy of Single Intravenous Infusion of JWK007 in Patients With Duchenne Muscular Dystrophy (DMD)
NCT06114056Duchenne Muscular Dystrophy
West China Hospital
Phase 1
3
Chengdu
2024-01-31
By invitation
Phase II Clinical Study of Contezolid for the Treatment of Bone and Joint Tuberculosis
NCT06811012Tuberculosis, Bone, Joint
Beijing Chest Hospital
Phase 1/2
24
Beijing
2024-01-31
Recruiting
Individualized Neoantigen Therapy with Unusual Radiotherapy Enhancement (iNATURE)
NCT06314087Advanced Tumors
The University of Hong Kong-Shenzhen Hospital
Phase 2
154
Shenzhen
2024-01-31
Recruiting
Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeM
NCT06543069Malignant Peritoneal Mesothelioma, Advanced
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
28
Beijing
2024-01-31
Recruiting
HUTT to Assess Cardiac Autonomic Nervous Function
NCT06236945Autonomic Nervous System Diseases
The First Hospital of Hebei Medical University
Observational
1,122
Shijiazhuang
2024-01-31
Recruiting
A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor
NCT06758557Advanced NSCLC, Advanced Endometrial Cancer
Huabo Biopharm Co., Ltd.
Phase 1/2
282
Baoding, Harbin, Luoyang, Zhengzhou, Lianyungang, Shenyang, Jinan, Linyi
2024-01-31
Not yet open
A Study of Cadonilimab Combined With AK112 as Second-line Therapy in Patients With Advanced Hepatocellular Carcinoma
NCT06196775Hepatocellular Carcinoma
Harbin Medical University
Phase 2
36
Harbin
2024-01-31
Recruiting
AMT-253 in Patients With Advanced Solid Tumours
NCT06209580Malignant Melanoma, Advanced Solid Tumors
Multitude Therapeutics Inc.
Phase 1/2
96
Beijing
2024-01-31
By invitation
The Novel Special Light for Endotracheal/Bronchial Lesions.
NCT07036614Tracheal Disease, Bronchial Disease
Shanghai Chest Hospital
Observational
400
Shanghai
2024-01-31
Recruiting
Application of EndoScell Intraoperative Cellular Probing Technology for Early-Stage Breast Cancer
NCT06911528Breast Cancer, Sentinel Lymph Node, Frozen Section, Cytology
Fudan University
Not applicable
709
Shanghai
2024-01-30
Not yet open
A Study of Simmitinib Plus SG001 in Advanced Solid Tumors
NCT06132217Advanced Solid Tumor
Shanghai Runshi Pharmaceutical Technology Co., Ltd
Phase 1/2
168
Beijing
2024-01-30
Recruiting
Study on the Role of Human Serum Albumin in Large Acute Ischemic Stroke of Anterior Circulation After Thrombectomy
NCT06629116Cerebral Ischemia
Tingyu-Yi
Not applicable
100
Zhangzhou
2024-01-30
Recruiting
Association Between Genetic Polymorphisms and Type 2 Asthma in Children
NCT06840717Asthma in Children, Genetic Disease, Inflammation
Guangzhou Institute of Respiratory Disease
Observational
300
Guangzhou
2024-01-30
Not yet open
Trastuzumab Deruxtecan (T-DXd) With Pyrotinib in First-line HER2-positive Unresectable or Metastatic Breast Cancer Trial
NCT06245824Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 4
51
Beijing
2024-01-30
Recruiting
Real Time Continuous Glucose Monitoring System in T2DM With Pregnacy
NCT05947916Type2diabetes, Pregnancy Related, Continuous Glucose Monitoring, Time in Range
Peking University Third Hospital
Not applicable
240
Beijing
2024-01-30
Rows per page Showing 13601–13700 of 19052
Previous 135 136 137 138 139 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site. Derived from ClinicalTrials.gov. Retrieved 23 September 2026. https://priyalifescience.com/clinical-trials-china?page=137

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →
→

Browse trials by condition

Breast Cancer (416) Advanced Solid Tumors (183) Gastric Cancer (183) Colorectal Cancer (179) Hepatocellular Carcinoma (161) Advanced Solid Tumor (159) Solid Tumor (145) Non-Small Cell Lung Cancer (144) Acute Ischemic Stroke (138) Lung Cancer (134) Pancreatic Cancer (132) Non-small Cell Lung Cancer (131) Multiple Myeloma (126) Coronary Artery Disease (111) Prostate Cancer (111)
→

Browse trials by site location

Beijing (5484) Shanghai (3827) Guangzhou (3318) Hangzhou (1812) Wuhan (1343) Chengdu (1291) Nanjing (1193) Changsha (1154) Chongqing (1056) Fuzhou (1018) Tianjin (940) Zhengzhou (921) Hefei (875) Jinan (785) Changchun (641)
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.